Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Aphex BioCleanse (SNST) Making Serious Headlines.
Relatively quiet for most of the year. Aphex BioCleanse, our favorite Super Bug sanitizer company, made two back-to-back announcements - signaling things...
Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).
Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR)
Summary
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21
Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
Adding Auris Medical (EARS) $3.50 to Biotech Watch List.
Auris Medical soared 590% in one Week on Covid Related News on December 1st, 2020.
LIFT OFF...
Aphex BioCleanse Further Expands Distribution Channels.
Aphex BioCleanse Systems Announces Partnership With Bifulco Consulting Group to Expand Distribution Channels
PITTSFORD, N.Y., May 20, 2021...
Citius Pharma (CTXR) Updates Shareholders.
Citius Update Stem Cell Study
Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
Aphex BioCleanse System’s (SNST) Significant Hand Sanitizer Purchase Order.
Aphex BioCleanse Systems Announces Significant Purchase Order for Proprietary, Alcohol-Free Hand Sanitizer Product
PITTSFORD, N.Y. , May 4, 2021 /PRNewswire/ -- Aphex...
Stem Cell Play Organicell (BPSR) Screams Higher.
Stock Levitates After Series of Positive Press Releases on Zofrin.
Added to the Watch List in April a...